Priya Singhal sold $532k of BIIB
Head of Development at BIOGEN INC.. 2,660 shares at an average of $199.83, traded Feb 9, 2026, filed Feb 10, 2026.
Score components
- +15RoleOfficer
- +18Trade size$532k at market
- +5Share of holdings soldSold 25% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.2%, 3m +5.5%, 6m +7.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875045-26-000023, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | MOption exercise Common Stock10b5-1 | +2,217 | $0.00 | $0 | 8,488 | Feb 10, 2026 |
| Feb 6, 2026 | FTax withholding Common Stock10b5-1 | -1,056 | $201.18 | $212k | 7,432 | Feb 10, 2026 |
| Feb 6, 2026 | MOption exercise Common Stock10b5-1 | +4,683 | $0.00 | $0 | 12,115 | Feb 10, 2026 |
| Feb 6, 2026 | FTax withholding Common Stock10b5-1 | -1,412 | $201.18 | $284k | 10,703 | Feb 10, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -2,660 | $199.83 | $532k | 8,043 | Feb 10, 2026 |
| Feb 6, 2026 | MOption exercise Restricted Stock Unitderivative10b5-1 | -2,217 | $0.00 | $0 | 2,217 | Feb 10, 2026 |
| Feb 6, 2026 | MOption exercise Restricted Stock Unitderivative10b5-1 | -4,683 | $0.00 | $0 | 9,367 | Feb 10, 2026 |
Related signals
Other insiders at BIOGEN INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 18Weak | BIOGEN INC. | Lloyd Minor director | $240k 1,186 shares | -31% | |
| 10Weak | BIIBbuy BIOGEN INC. | Nicole Murphy Head of Pharm Ops and Tech | $585 3 shares | +0% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $134k 748 shares | -11% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $69k 517 shares | -8% | |
| 19Weak | BIOGEN INC. | Rachid Izzar Head of Global Product Strat. | $300k 2,223 shares | -26% | |
| 23Weak | BIOGEN INC. | Priya Singhal Head of Development | $481k 3,806 shares | -41% | |
| 44Moderate | BIIBbuy BIOGEN INC. | Caroline Dorsa director | $152k 1,235 shares | +5% | |
| 30Weak | BIOGEN INC. | Stephen A Sherwin director | $1.3M 8,760 shares | -44% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $17k 110 shares | -2% | |
| 0Weak | BIOGEN INC. | Priya Singhal Head of Development | $88k 431 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.